AARD today
$1.58-$0.01 (-0.31%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $5.88
Key levels
Resistance$3.65
Resistance$1.59
Support$1.09
Latest news & SEC filings
SEC FilingAardvark Therapeutics, Inc. filed an insider trading report (Form 4)
AnalystAardvark Therapeutics cut to Market Perform by Raymond James
All AARD news →About Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company that designs small-molecule medicines intended to trigger bitter taste receptors in the digestive tract, aiming to treat metabolic disorders. Its main experimental drug, ARD-101, is taken by mouth and stays largely in the gut, and is being studied for excessive hunger tied to Prader-Willi Syndrome. A second program, ARD-201, combines ARD-101 with another agent for obesity and related conditions. The company runs trials across North America, Europe, Asia and Australia.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
Aardvark Therapeutics, Inc. (AARD)
What Is the Price Target for AARD?
SEPT Low Target
$3.40
SEPT Mid Target
$4.00
SEPT High Target
$4.60
Analyst Consensus
$4.00
Is AARD a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AARD.
Start Free Trial →Is AARD Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$3.35
17
Moat Score
NONE
1/9
Piotroski Score
2.8
Altman Z-Score
What Is Smart Money Doing with AARD?
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sun Nelson | officer | Sale | 62,000 | $321K | Sep 11, 2026 |
| Sun Nelson | officer | Sale | 14,754 | $74K | Sep 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AARD Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
43.11%
FCF Growth YoY
-198.2%
Revenue Trend
UNKNOWN
Dark Pool Trades for AARD
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AARD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:22:01 | $1.57 | 5,000 | $$8K | BUY |
| 17:21:57 | $1.57 | 5,000 | $$8K | BUY |
| 16:38:47 | $1.54 | 14,000 | $$22K | BUY |
| 16:29:54 | $1.56 | 3,205 | $$5K | BUY |
| 14:51:20 | $1.55 | 1,625 | $$3K | SELL |
5 dark pool trades shown · $$45K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aardvark Therapeutics, Inc. (AARD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AARD — frequently asked questions
What is AARD stock price today?
Aardvark Therapeutics, Inc. (AARD) is at $1.58, down 0.31% (-$0.01) at the Nov 12, 2026 close.
Why is AARD stock moving today?
Latest AARD news — Nov 10, 2026: Aardvark Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: Aardvark Therapeutics cut to Market Perform by Raymond James
What is the AARD price target?
The average analyst price target for AARD is $4.00, ranging from $3 to $7, based on 3 analysts. Latest: HC Wainwright & Co. maintains on Oct 19, 2026.
What do analysts rate AARD?
Analyst ratings for AARD: 0 Buy, 2 Hold, 2 Sell — consensus Hold.
Did AARD beat earnings?
AARD last reported on Aug 11, 2026: EPS -$0.66 vs -$0.87 expected — a beat of 24.5%.
Does AARD pay a dividend?
AARD does not currently pay a dividend.
What are AARD support and resistance levels?
Support: $1.09. Resistance: $1.59, $3.65, $4.10.
What are insiders doing with AARD?
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
What is the latest news on AARD?
Nov 10, 2026: Aardvark Therapeutics, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: Aardvark Therapeutics cut to Market Perform by Raymond James